NIK SMI1 is an effective and selective NF-κB inducing kinase (NIK) inhibitor. It also inhibits NIK-catalyzed hydrolysis of ATP to ADP (IC50: 0.23±0.17 nM).
| Pack Size | Availability | Price/USD | Quantity |
|---|---|---|---|
| 1 mg | In stock | $ 237 | |
| 2 mg | In stock | $ 426 | |
| 4 mg | In stock | $ 603 | |
| 10 mg | In stock | $ 1150 | |
| 20 mg | In stock | $ 1794 |
| Description | NIK SMI1 is an effective and selective NF-κB inducing kinase (NIK) inhibitor. It also inhibits NIK-catalyzed hydrolysis of ATP to ADP (IC50: 0.23±0.17 nM). |
| In vitro | NIK SMI1 inhibits the expression of NIK SMI1 response element regulated firefly luciferase reporter gene in HEK293 cells (IC50: 34±6 nM). NIK SMI1 inhibits BAFF-induced B cell (mouse) survival in vitro with an IC50 of 373±64 nM. Consistent with expectations for a NIK inhibitor, NIK SMI1 is shown to inhibit nuclear translocation of p52 (RelB) (IC50=70 nM). |
| In vivo | The pharmacology of NIK SMI1 is examined in SD rat, CD-1 mouse, beagle, and cynomologous monkey with 20, 32, 18, and 7.8 mL/kg per min, respectively. The volume of distribution (Vd, L/kg) is 1.35, 1.58, 0.778, and 1.39, respectively. C57BL/6 mice are treated twice daily for 7 days with orally administered NIK SMI1 or with three injections of recombinant BAFF receptor fusion protein (Br3- mIgG2a) over the course of the 7-day experiment as a positive control . |
| CAS No. | 1660114-31-7 |
| Chemical Formula | C20H19N3O4 |
| Molecular Weight | 365.389 |
| Solubility | DMSO: 100 mg/mL (273.69 mM), Need ultrasonic |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
In vivo Formulation Calculator (Clear solution)Calculatorbottom
